Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.6.3.1 (
Mg2+-ATPase
)
1,484
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The essential role for phosphatidylinositol-4-phosphate (
PtdIns
(4)P) in vesicle-mediated protein transport from the trans-Golgi network (TGN) was first described in the budding yeast Saccharomyces cerevisiae. However, the identity of downstream effectors of
PtdIns
(4)P in this system has been elusive. Here, we show that Drs2p, a type IV P-type ATPase required for phospholipid translocase (
flippase
) activity and transport vesicle budding from the TGN, is an effector of
PtdIns
(4)P. Drs2p-dependent flip of a fluorescent phosphatidylserine analogue across purified TGN membranes requires synthesis of
PtdIns
(4)P by the phosphatidylinositol-4-kinase (PI(4)K) Pik1p.
PtdIns
(4)P binds to a regulatory domain in the C-terminal tail of Drs2p that has homology to a split PH domain and is required for Drs2p activity. In addition, basic residues required for phosphoinositide binding overlap a previously mapped binding site for the ArfGEF Gea2p. ArfGEF binding to this C-terminal domain also stimulates
flippase
activity in TGN membrane preparations. These interactions suggest the presence of a coincidence detection system used to activate phospholipid translocation at sites of vesicle formation.
...
PMID:Regulation of a Golgi flippase by phosphoinositides and an ArfGEF. 1989 64
